¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Nucleic acids research. Supplement (2001)"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 3 ÆäÀÌÁö: 1
¿µ¹® VDRL(venereal disease research laboratory) ÇÑ±Û ¼ºº´ ¿¬±¸½ÇÇè½Ç
¼³¸í   
  ¸Åµ¶±ÕÀÇ reagin¿¡ ´ëÇÑ Ç×ü. ¸Åµ¶ÀÇ ¼±º°°Ë»ç·Î »ç¿ëµÇ¸ç ¸Åµ¶ Ä¡·á¿¡ ´ëÇÑ ¹ÝÀÀ ¿©ºÎ¿Í Ä¡·áÈ¿°ú ÆÇÁ¤¿¡µµ »ç¿ëµÈ´Ù. ¸Åµ¶¿Ü¿¡µµ Àü½Å¼ºÈ«¹Ý¼º³¶Ã¢, ·ù¸¶Æ¼½º°üÀý¿° µî¿¡¼­µµ ¾ç¼ºÀ¸·Î ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
¿µ¹® amino acids ÇÑ±Û ¾Æ¹Ì³ë»ê
¼³¸í   
  ¾Æ¹Ì³ë±â(£­NH3)¿Í Ä«¸£º¹½Ç±â(£­COOH)¸¦ °¡Áö°í Àִ ¸ðµç À¯±â¹°Áú. ´Ü¹éÁúÀ» ÀÌ·ç´Â ±âº»´ÜÀ§°¡ µÈ´Ù. ÁܹéÁúÀº ¾Æ¹Ì³ë»êÀÌ ¿¬°áµÇ¾î¼­ ÀÌ·ç´Â °ÍÀÌ´Ù. ÀÎü¿¡¼­´Â ¾Æ¹Ì³ë»êÀÌ ´Ü¹éÁúÀÇ ±âº»´ÜÀ§°¡ µÇ´Â °Í¿Ü¿¡ ½Å°æ¼¼Æ÷¿Í ½Å°æ¼¼Æ÷°¡ ¼­·Î ¿¬¶ôÀ» ÁÖ°í ¹Þ´Âµ¥ ¾²À̴ ½Å°æÀü´Þ¹°Áú·Î¼­ÀÇ ¿ªÇÒµµ ÇÑ´Ù. »ç¶÷ÀÇ ´Ü¹éÁúÀº 20°¡ÁöÀÇ ¾Æ¹Ì³ë»êÀ¸·Î ±¸¼ºµÈ´Ù. Áï »ç¶÷¿¡ À־ ´Ü¹éÁúÀ» ÇÕ¼ºÇϴ µ¥´Â 20°¡ÁöÀÇ ¾Æ¹Ì³ë»êÀÌ ÇÊ¿äÇÏ´Ù. ¿©±â¿¡¼­ 11°¡Áö´Â ÀÎü³»¿¡¼­ Á÷Á¢ ÇÕ¼ºÇÒ ¼ö ÀÖÁö¸¸ ³ª¸ÓÁö 9°¡Áö´Â ÇÕ¼ºÇÒ ¼ö ¾ø°í ¹Ýµå½Ã À½½Ä¹°¿¡¼­ ¼·ÃëÇØ¾ß ÇÑ´Ù. À̰ÍÀ» Çʼö¾Æ¹Ì³ë»êÀ̶ó°í ÇÑ´Ù.
¿µ¹® nucleic acid ÇÑ±Û ÇÙ»ê
¼³¸í   
  ¿°±â, ´ç, ÀλêÀ¸·Î ÀÌ·ç¾îÁø ´ºÅ¬·¹¿ÀƼµå°¡ ±ä »ç½½ ¸ð¾çÀ¸·Î ÁßÇյȠ°íºÐÀÚ ¹°Áú. À¯ÀüÀ̳ª ´Ü¹éÁú ÇÕ¼ºÀ» Áö¹èÇϴ Áß¿äÇÑ ¹°Áú·Î, »ý¹°ÀÇ Áõ½ÄÀ» ºñ·ÔÇÑ »ý¸í È°µ¿ À¯Áö¿¡ Áß¿äÇÑ ÀÛ¿ëÀ» ÇÑ´Ù. ±¸¼º ´çÀΠ¿Àź´çÀÌ ¸®º¸¿À½ºÀΠ¸®º¸ÇÙ»ê°ú µð¿Á½Ã¸®º¸¿À½ºÀΠµð¿Á½Ã¸®º¸ ÇÙ»êÀ¸·Î ³ª´¶´Ù. ÆæÅ佺·Î¼­ ¸®º¸½º³ª µ¥¿Á½Ã¸®º¸½º ¾î´À ÇÑÂʸ¸À» Æ÷ÇÔÇϸç ÀüÀÚ¸¦ ¸®º¸ÇÙ»ê(RNA), ÈÄÀÚ¸¦ µ¥¿Á½Ã¸®º¸ÇÙ»ê(deoxyribonucleic acid, DNA)À̶ó ºÎ¸¥´Ù. ¸ðµÎ 4Á¾·ùÀÇ À¯±â¿°±â¿¡ ÀÇÇØ Æ¯Â¡Áö¾îÁö¸ç ¾Æµ¥´Ñ, ±¸¾Æ´Ñ ¹× ½ÃÅä½ÅÀº ¾çÀÚ¿¡ °øÅëÀÌ´Ù. Æ¼¹ÎÀº DNA¿¡, ¿ì¶ó½ÇÀº RNA¿¡ Æ÷ÇԵȴÙ. DNA´Â ÁַΠÇÙ¿¡ Á¸ÀçÇϸç ÇüÁúÀ¯Àü¿¡ ±×¸®°í RNA´Â ¼¼Æ÷Áú¼Ó¿¡¼­ ´Ü¹éÁú ÇÕ¼º¿¡ °ü¿©ÇÑ´Ù. ¼·ÃëµÈ ÇÙ»êÀº ¼ÒÈ­°ü¿¡¼­ ±¸¼ººÐÀڷαîÁö °¡¼öºÐÇØµÇ¾î Èí¼öµÈ´Ù.
  
  
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 6 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • nucleic acid
    ÇÙ»ê
  • nucleic acid probe
    ÇÙ»ê´õµëÀÚ
  • research
    ¿¬±¸
  • research design
    ¿¬±¸°èȹ
  • research diagnostic criteria
    ¿¬±¸Áø´Ü±âÁØ
  • venereal disease research laboratory test
    ¸Åµ¶Ç÷û°Ë»ç, VDRL°Ë»ç
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 3 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • nucleic acid
    ÇÙ»ê
  • research
    ¿¬±¸
  • diagnostic research
    Áø´Ü¿¬±¸
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 8 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • nucleic acid
    ÇÙ»ê
  • nucleic acid hybridization
    ÇÙ»êºÎÇÕÈ­
  • nucleic acid probe
    ÇÙ»ê´õµëÀÚ
  • research diagnostic criteria
    ¿¬±¸Áø´Ü±âÁØ
  • research design
    ¿¬±¸°èȹ
  • operational research
    ÀÛÀü¿¬±¸
  • research
    ¿¬±¸
  • venereal disease research laboratory test
    ¸Åµ¶Ç÷û°Ë»ç
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 9 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • hybridization, nucleic acid
    ÇÙ»êºÎÇÕ¹ý(ݬùêÛö)
  • FFA (free fatty acids)
    À¯¸®(ë´×î)Áö¹æ»ê(ò·Û¸ß«)
  • Free fatty acids
    À¯¸®Áö¹æ»ê(ë´×îò·Û¸ß«)
  • Ketogenic amino acids
    ÄÉÅæÃ¼Çü¼º(¡­û¡à÷)¾Æ¹Ì³ë»ê(¡­ß«)
  • Lipid Research Clinic
    ÁöÁú¿¬±¸Áø·á¼Ò
  • RDC, see Research Diagnostic Criteria
    ¿¬±¸Áø´Ü±âÁØ, ¿¬±¸¿ë Áø´Ü±âÁØ
  • VDRL test= venereal disease research laboratory test
    ¼ºº´¿¬±¸¼Ò½ÄÅ×½ºÆ®.
  • VDRL test= venereal disease research laboratory test
    ¼ºº´¿¬±¸¼Ò½ÄÅ×½ºÆ®.
  • alpha hydroxy acids
    ¾ËÆÄÈ÷µå·Ï½Ã»ê
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • research diagnostic criteria(RDC)
    ¿¬±¸Áø´Ü±âÁØ
  • venereal disease research laboratory test =VDRL test
    ¼ºº´¿¬±¸¼Ò½ÄÅ×½ºÆ®.
  • venereal disease research laboratory test =VDRL test
    ¼ºº´¿¬±¸¼Ò½ÄÅ×½ºÆ®.
  • alpha hydroxy acids
    ¾ËÆÄÈ÷µå·Ï½Ã»ê
  • essential amino acids
    Çʼö¾Æ¹Ì³ë»ê.
  • essential fatty acids
    ÇʼöÁö¹æ»ê.
  • fatty acids
    Áö¹æ»ê
  • hybridization, nucleic acid
    ÇÙ»êºÎÇÕ¹ý(ݬùêÛö)
  • lipoteichoic acids
    Lipoteichoic acids
  • metabolic defect of nucleic acid (purinemia)
    ÇÙ»ê´ë»ç°áÇÔ(Ç»¸°Ç÷Áõ)
  • nucleic acid hybridization
    ÇÙ»êºÎÇÕ¹ý(~ݬùêÛö)
  • nucleic acid probe
    ÇÙ»êÇÁ·Î¿ìºê
  • nucleic acid probe
    ÇٻꎽÄÀÚ
  • pentose nucleic acid
    ÆæÅ佺ÇÙ»ê.
  • total fatty acids
    ÃÑÁö¹æ»ê(õÅò·Û¸ß«).
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Metabolic defect of nucleic acid (Purinemia)
    ÇÙ»ê´ë»ç°áÇÔ(Ç»¸°Ç÷Áõ)
    [¿¾ ¿ë¾î] ÇÙ»ê´ë»ç°áÇÔ(Ç»¸°Ç÷Áõ)
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 13 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • deoxyribose nucleic acid
    "µ¥¿Á½Ã¶óÀ̺¸½º ÇÙ»ê(ú·ß«), (ÔÒ) deoxyribonucleic acid"
  • infectious nucleic acid
    °¨¿°¼ºÇÙ»ê(Êïæøàõú·ß«)
  • nucleic acid
    ÇÙ»ê(ú·ß«)
  • nucleic acid bases
    Çٻ꿰±â(ú·ß«ç¤Ðñ)
  • pentose nucleic acid
    "ÆæÅ佺(¿Àź´ç,çé÷©ÓØ) ÇÙ»ê(ú·ß«)"
  • ribose nucleic acid
    ¶óÀ̺¸½º ÇÙ»ê(ú·ß«)
  • casamino acids
    Ä«»ç¹Ì³ë»ê(ß«)
  • free fatty acids
    À¯¸® Áö¹æ»ê(ë´×îò·Û¸ß«)
  • mercapturic acids
    ¸ÓİÅõ·ç»ê(ß«)
  • nonessential amino acids
    ºñÇʼö(Þªù±áó)¾Æ¹Ì³ë»ê
  • standard amino acids
    Ç¥ÁØ(øöñÞ) ¾Æ¹Ì³ë»ê(ß«)
  • ustilagic acids
    ¿ì½ºÆ¿¶ó±× »ê(ß«)
  • very long-chain fatty acids
    ¸Å¿ì ±ä »ç½½ Áö¹æ»ê(ò·Û¸ß«)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • supplement
    º¸Ãæ
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
CuS copper supplement
ECGS endothelial cell growth supplement
GIS gas in stomach; gastrointestinal series; geographic information system; guaranteed income supplement...
HCTS high cholesterol and tocopherol supplement
HPS Hantavirus pulmonary syndrome; hematoxylin, phloxin, and saffron; Hermansky-Pudlak syndrome; high-pr...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
ECGS Endothelial Cell Growth Supplement
NASBA Nucleic Acid Sequence Based Amplification
NA Nucleic acid
NAT Nucleic acid testing
PNA Peptide Nucleic Acid
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • JrId: 30388
    JournalTitle: Nucleic acids research. Supplement (2001)
    MedAbbr: Nucleic Acids Res Suppl
    ISSN:
    ESSN:
    IsoAbbr: Nucleic Acids Res. Suppl.
    NlmId: 101169367
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 8 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • supplement
    º¸Ãæ
  • total fatty acids
    ÃÑ Áö¹æ»ê
  • clinical research
    ÀÓ»ó ¿¬±¸
  • pain research laboratory
    µ¿Åë ¿¬±¸¼Ò
  • preclinical research
    ÀÓ»ó Àü ¿¬±¸
  • research
    ¿¬±¸, Á¶»ç
  • The National Institute of Dental Research
    ±¹¸³ Ä¡ÀÇÇÐ ¿¬±¸¼Ò
  • VDRL : Venereal Disease Research LaboratoryÀÇ ¾àÀÚ. ¸Åµ¶±ÕÀÇ Reagin¿¡ ´ëÇÑ Ç×ü·Î, ¸Åµ¶ÀÇ ¼±º°°Ë»ç·Î »ç¿ëµÇ¸ç ¸Åµ¶ Ä¡·á¿¡ ´ëÇÑ ¹ÝÀÀ ¿©ºÎ°¡ Ä¡·á È¿°ú ÆÇÁ¤¿¡ »ç¿ëµÈ´Ù. ¸Åµ¶ ¿Ü¿¡µµ Àü½Å¼º È«¹Ý¼º ³¶Ã¢(SLE), ·ù¸¶ÅäÀÌµå °üÀý¿° µî¿¡¼­µµ ¾ç¼ºÀ¸·Î ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
    VDRL ¸é»ó ¹ÝÀÀ
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
supplement Something that supplies a want or make an addition: something that completes, adds a finishing touch or brings closer to completion or a desired state.
(18 Nov 1997)
nucleic acids Highly complex portions of nucleoproteins that yield a mixture of purines and pyrimidines, a ribose or deoxyribose component, and phosphoric acid on complete hydrolysis. The two general types are ribonucleic acid (RNA) and deoxyribonucleic acid (DNA).
(12 Dec 1998)
nucleic acids, nucleotides, and nucleosides Complex compounds of high molecular weight occurring in living cells. These are basically of two types, ribonucleic (RNA) and deoxyribonucleic (DNA) acids, both of which consist of nucleotides (nucleoside phosphates linked together by phosphate bridges).
(12 Dec 1998)
regulatory sequences, nucleic acid DNA sequences involved in regulating the expression of other genes.
(12 Dec 1998)
repetitive sequences, nucleic acid Nucleotide sequences present in multiple copies in the genome. They include direct, inverted, tandem, and terminal repeat sequences and the alu family repeat (named for the restriction endonuclease cleavage enzyme alu I).
(12 Dec 1998)
minus-strand nucleic acid <molecular biology> An RNA or DNA strand which has the opposite sense of (would be complementary to) the mRNA of a virus.
(12 Jan 1998)
sequence homology, nucleic acid The sequential correspondence of nucleotide triplets in a nucleic acid molecule which permits nucleic acid hybridization. Sequence homology is important in the study of mechanisms of oncogenesis and also as an indication of the evolutionary relatedness of different organisms. The concept includes viral homology.
(12 Dec 1998)
nucleic acid <biochemistry, molecular biology> Linear polymers of nucleotides, linked by 3', 5' phosphodiester linkages. In DNA, deoxyribonucleic acid, the sugar group is deoxyribose and the bases of the nucleotides adenine, guanine, thymine and cytosine. RNA, ribonucleic acid, has ribose as the sugar and uracil replaces thymine. DNA functions as a stable repository of genetic information in the form of base sequence. RNA has a similar function in some viruses but more usually serves as an informational intermediate (mRNA), a transporter of amino acids (tRNA), in a structural capacity or, in some newly discovered instances, as an enzyme.
The spontaneous loss of the amino groups of cytosine (yielding uracil), methyl cytosine (yielding thymine) or of adenine (yielding hypoxanthine). It can be argued that the presence of thymine in DNA in place of the uracil of RNA stabilises genetic information against this lesion, since repair enzymes would restore the GU base pair to GC.
(18 Nov 1997)
nucleic acid base A purine or pyrimidine; found in naturally occurring nucleic acids such as DNA.
(05 Mar 2000)
nucleic acid conformation The characteristic 3-dimensional shape of a nucleic acid or polynucleotide. Its secondary structure is due to the formation of hydrogen bonds between nucleotides, resulting in base pairing and areas with alpha helix structure.
(12 Dec 1998)
nucleic acid denaturation Disorganization of secondary structures of nucleic acids through cleavage of hydrogen bonds and hydrophobic linkages. Denatured DNA appears to be a single-stranded flexible structure. The effects of denaturation on RNA are similar though less pronounced and largely reversible.
(12 Dec 1998)
nucleic acid heteroduplexes Double-stranded nucleic acid molecules (DNA-DNA or DNA-RNA) which contain regions of nucleotide mismatches (non-complementary). In vivo, these heteroduplexes can result from mutation or genetic recombination; in vitro, they are formed by nucleic acid hybridization. Electron microscopic analysis of the resulting heteroduplexes facilitates the mapping of regions of base sequence homology of nucleic acids.
(12 Dec 1998)
nucleic acid hybridization Widely used technique which exploits the ability of complementary sequences in single-stranded dnas or rnas to pair with each other to form a double helix. Hybridization can take place between two complimentary DNA sequences, between a single-stranded DNA and a complementary RNA, or between two RNA sequences. The technique is used to detect and isolate specific sequences, measure homology, or define other characteristics of one or both strands. (kendrew, encyclopedia of molecular biology, 1994, p503; dorlands, 28th ed, p781)
(12 Dec 1998)
nucleic acid precursors Use for nucleic acid precursors in general or for which there is no specific heading.
(12 Dec 1998)
nucleic acid probe A nucleic acid fragment, labelled by a radioisotope, biotin, etc., that is complementary to a sequence in another nucleic acid (fragment) and that will, by hydrogen binding to the latter, locate or identify it and be detected; a diagnostic technique based on the fact that every species of microbe possesses some unique nucleic acid sequences which differentiate it from all others, and thus can be used as identifying markers or "fingerprints."
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • nucleic acid
    (»ýÈ­)ÇÙ»ê
  • supplement
    º¸À¯
  • Earnings Related Supplement
    (¿µ)º¸Çè ±ÞºÎ±Ý(¿µ±¹ÀÇ »çȸº¸ÀåÁ¦µµ¿¡¼­ 6°³¿ù°£ ½Ç¾÷ÀÚ(ȯÀÚ)¿¡°Ô Àü³âµµ ¼Òµæ¿¡ µû¶ó Áö±ÞµÊ)
  • color supplement
    (½Å¹® µîÀÇ)Ä÷¯ÆÇ ºÎ·Ï
  • supplement
    º¸Ãæ;º¸Á·;º¸À¯;ºÎ·Ï(to)
  • research
    ¿¬±¸
  • listener research
    Àαâ ÇÁ·ÎÁ¶»ç
  • market research
    (Á¦Ç°À» ¸ÅÃâÇϱâ ÀüÀÇ) ½ÃÀå Á¶»ç
  • market research
    ½ÃÀå Á¶»ç (¾î¶² »óǰÀÇ ¼ö¿ä¸¦ À§ÇÑ »çÀü Á¶»ç)
  • marketing research
    ½ÃÀå Á¶»ç;½ÃÀå ºÐ¼®
  • motivational research
    µ¿±â Á¶»ç
  • operations research
    ±â¾÷ °æ¿µ»óÀÇ °úÇÐÀû Á¶»ç ¿¬±¸;ÀÛÀü ¿¬±¸
  • research
    (Çмú)¿¬±¸;°úÇÐÀû ޱ¸;ÇмúÁ¶»ç;(½ÅÁßÇÑ)¼ö»ö;ޱ¸;Á¶»ç;¿¬±¸ ´É·Â;¿¬±¸½É;¿¬±¸ÇÏ´Ù;Á¶»çÇÏ´Ù;~able
  • research and development
    ¿¬±¸¿Í °³¹ß
  • research laboratory(institute)
    ¿¬±¸¼Ò
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á